Brugel

Quick links to important sections

Brugel

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brugel

Property Description
Active ingredient Flurbiprofen
Form Topical Gel (Semisolid)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of Pain and Inflammation
Origin Synthetic (Propionic acid derivative)

Brugel: Classification as a Topical NSAID

Brugel is a pharmaceutical preparation classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose active substance is Flurbiprofen. This medication is defined by its core ingredient, Flurbiprofen, which is a synthetic compound belonging to the propionic acid derivative chemical family. The product is characterized as a single-active ingredient drug, focusing on the therapeutic action of this chemical agent.

The Significance of the Flurbiprofen Gel Form

Brugel is formulated as a topical gel, a semisolid dosage form specifically designed for external use and local application to the skin. This formulation utilizes the topical route of administration, which means the active component, Flurbiprofen Topical, is engineered to absorb directly into the tissues beneath the application site. The gel base facilitates the direct delivery of the drug's properties to the target area, such as a localized muscle sprain or joint discomfort. This method of localized delivery allows for concentration of the analgesic and anti-inflammatory effects precisely where they are needed, which is often considered beneficial for minimizing the overall body exposure associated with ingested NSAIDs.

What is the General Purpose of Brugel?

The general purpose of Brugel is to provide focused relief by acting as an anti-inflammatory and analgesic agent for localized tissue distress. The functionality of Flurbiprofen is based on its ability to inhibit the biosynthesis of prostaglandins, which are critical chemical messengers that drive the processes of pain and swelling. By blocking the activity responsible for producing these mediators, the medicine's core therapeutic benefit is to reduce the severity of these symptoms, offering targeted support to relieve the discomfort and stiffness associated with localized inflammatory responses.

What side effects are possible with Brugel?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety constraints associated with Brugel (Flurbiprofen) as documented in official government regulatory information.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by the likelihood of occurrence, based on regulatory definitions:

  • Common (may affect up to 1 in 10 people): Gastrointestinal disturbances (e.g., nausea, diarrhoea, dyspepsia, abdominal pain), headache, dizziness, fatigue, and oedema (fluid retention).
  • Uncommon (may affect up to 1 in 100 people): Hypersensitivity reactions, anaemia, visual impairment, gastritis, or mild skin reactions (rash, pruritus).
  • Rare/Very Rare: These include critical reactions such as anaphylactic reactions, severe renal or hepatic failure, and serious blood disorders (e.g., agranulocytosis).

Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions (SARs) are rare but clinically significant and are documented in official labeling, including:

  • Gastrointestinal Events: Bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
  • Cardiovascular Events: Increased risk of serious thrombotic events, including myocardial infarction and stroke.
  • Severe Skin Reactions: Potentially fatal conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Restrictions and Limitations

The medicine is contraindicated (should not be used) in several specific situations, including:

  • The third trimester of pregnancy.
  • In patients with active or a history of recurrent peptic ulcer/haemorrhage.
  • In the setting of peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery.
  • In patients with severe heart, kidney, or liver failure.

Population-Specific Safety Notes

Elderly patients are at an increased risk of serious adverse reactions, particularly fatal gastrointestinal bleeding and kidney impairment. Use in this population requires careful consideration and monitoring.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Overdose from Flurbiprofen, the active ingredient in Brugel, may lead to systemic effects typically manifesting as nausea, vomiting, epigastric pain, lethargy, and drowsiness. These specific clinical presentations are documented in regulatory labeling as the primary signs of toxicity, which are generally reversible with supportive care.

However, the official profile also details the potential for rare but severe systemic outcomes that necessitate urgent intervention. These serious manifestations include gastrointestinal bleeding, acute renal failure, respiratory depression, and coma. Patients must seek emergency medical attention immediately upon suspicion of an overdose.

Contacting a Poison Help line is mandated for professional guidance on managing the event. Management relies on symptomatic and supportive care as no specific antidote is listed in the official prescribing information. In cases of significant exposure seen within four hours, procedures such as activated charcoal administration may be considered for decontamination. Notably, elderly patients and individuals with a prior history of GI bleeding are officially identified as being at a greater risk for serious adverse events following an NSAID overdose.

Therapeutic Uses of Brugel

What Brugel Treats: Main Uses and Benefits

Brugel (Flurbiprofen Topical Gel) is commonly used in situations involving certain distressing symptoms across common musculoskeletal and joint conditions. It is applied in contexts where additional symptomatic support is needed, focusing exclusively on symptoms related to inflammatory or irritative states. Its use is considered relevant for easing symptoms linked to joint and muscle distress.

The medication may assist in addressing symptom clusters that may become intense or disruptive, including localized pain, inflammatory swelling, and tenderness. It is commonly used for conditions presenting with acute episodes like muscle strains, ligament sprains, and contusions, as well as for chronic issues such as osteoarthritis, tendinitis, and bursitis.

Its use is relevant for easing symptoms that may become more disruptive during flare-ups in specific, affected areas.

This symptomatic assistance may contribute to improved comfort during periods of heightened symptoms by easing the overall symptom load.


Quick Fact: Relief for Localized Pain

Brugel is applied when symptoms create noticeable interference with daily comfort, and may support the patient during difficult episodes by easing distress, and assists with managing symptoms that interfere with daily functioning.

Regulatory References

  1. NIH DailyMed product labeling for topical Flurbiprofen

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults
  • Adolescents aged 12 years and older (where product labeling permits)

Populations for whom use is contraindicated:

  • Individuals with known hypersensitivity to Flurbiprofen, aspirin, or any other NSAID (including those with asthma, urticaria, or allergic-type reactions in response to these agents).
  • Patients in the last trimester of pregnancy (beginning at 30 weeks gestation).
  • Patients with severe heart failure, severe hepatic impairment (liver), or severe renal impairment (kidney).
  • Patients with active, or history of recurrent peptic ulcer/haemorrhage (stomach or intestinal bleeding).
  • Patients receiving treatment for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age-related eligibility rules:

  • Children under 12 years of age are generally not indicated for use, as safety and efficacy have not been established.
  • Elderly patients (65 years and older) are eligible but are classified as a population at increased risk of serious adverse consequences.

Eligibility-Related Restrictions

  • Conditional Use: The medicine must be used with caution in patients with mild to moderate organ impairment, uncontrolled hypertension, or a history of heart failure (non-severe).
  • Pregnancy and Lactation: Use is not recommended during breastfeeding or for women who are attempting to conceive. Application is prohibited on wounds or damaged skin.

Connection to the overall eligibility profile: Regulatory documents define eligibility primarily by imposing absolute prohibitions based on severe systemic risks associated with the NSAID class, particularly in relation to allergies, organ function, and late-stage pregnancy. For other populations, such as the elderly, use is permitted but explicitly tagged with requirements for caution.

What should I know about interactions with other medicines?

Brugel’s interaction profile is documented in official regulatory sources and reflects the systemic risks associated with its active ingredient, Flurbiprofen, a Non-Steroidal Anti-Inflammatory Drug (NSAID). Restrictions are formally stated for several substance and medicine combinations.

The medicine is contraindicated in the peri-operative setting of coronary artery bypass graft (CABG) surgery. The use of other NSAIDs or high-dose Aspirin concurrently is not generally recommended due to the potential for additive gastrointestinal risks.

Documented interactions are classified based on the regulatory outcome:

Interaction Category Interacting Medicines Official Outcome
Increased Toxicity Risk Lithium, Methotrexate Decreased renal elimination of the co-administered drug, increasing plasma concentrations.
Pharmacodynamic Risk Anticoagulants, Anti-platelet Agents, SSRIs Synergistic effect increasing the risk of serious bleeding.
Reduced Drug Effect ACE Inhibitors, ARBs, Diuretics Diminishes the antihypertensive or natriuretic effect of the co-administered drug.

Regarding substances, consumption of alcohol may increase the undesirable effects related to the active ingredient, especially those concerning the gastrointestinal tract. Additionally, official documents caution that co-administration with ACE Inhibitors or ARBs requires monitoring in the elderly or those with renal impairment due to the risk of renal function deterioration.

Mechanism of Action

Brugel works by a highly localized mechanism that targets the core biochemical process driving peripheral inflammation and nociceptive sensitivity.

Interruption of Prostaglandin Biosynthesis

This domain defines the core mechanistic step: reversible inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking the COX enzymes, the drug prevents the conversion of arachidonic acid into prostanoids, which are key chemical mediators. This interruption of the Prostaglandin Synthesis Pathway modifies the molecular steps that lead to local tissue signaling and peripheral nerve sensitization.

️ Alteration of Peripheral Nociceptive Signaling

The resulting reduction in local prostaglandin ( PGE2) concentration alters the signaling dynamics of the peripheral nociceptive pathway. Prostaglandins typically sensitize local nerve endings (nociceptors), causing a state of heightened pain response (hyperalgesia). By limiting this sensitization, the drug contributes to the modulation of activity within the peripheral nociceptive pathways, which is the mechanism that functionally attenuates peripheral hyperalgesia.

Regulation of Local Vascular Responses

The mechanism further influences localized physiological responses by impacting vascular permeability and blood vessel tone. Reduced prostanoid levels limit the chemical signals that cause fluid to leak from local capillaries into the tissue space. This modification of the localized microcirculation limits the impact of excessive mediator activity, leading to attenuation of fluid accumulation (edema) in the tissue.

Dosage and Administration Information

How to Use Brugel: Official Administration Guidelines

Brugel, a topical gel containing Flurbiprofen, is an external medication with established administration guidelines for this dosage form. The instructions focus on localized application, a fixed dosing schedule, and restricted use in specific populations.


Feature Official Labeled Instruction
Route of Administration Topical (Designed for local application to the skin).
Dosing Schedule Apply a sufficient amount to cover the affected area. The dosage should be the lowest effective dose for the shortest duration necessary.
Frequency Application is typically prescribed to be performed twice daily.
Procedural Condition The gel must be applied directly to the affected area and is intended strictly for external use only.
Age Restriction Administration is not recommended in children under the age of 12 years. Specific guidance should be sought for pediatric patients.
Missed Dose If a scheduled application is missed, guidelines advise against applying a double dose to compensate. Users should return to their regular schedule.

Resulting Procedural Structure

  • The application process begins by locating the targeted area of the body.
  • A single, appropriate dose is then applied directly to the skin at that site.
  • This application procedure is repeated consistently at the established twice-daily frequency.

This structure establishes a localized and time-limited therapeutic protocol, ensuring the product is used in accordance with the established application parameters.

Recent Clinical Evidence

Recent Clinical Evidence


Summary of Clinical Trials

This section summarizes the key research on the drug Brugel. The drug's clinical development program included multiple Phase 2 and Phase 3 trials enrolling thousands of participants across several countries.

  • Phase 1 studies focused on safety and how the drug is processed by the body (pharmacokinetics) in healthy volunteers.
  • Phase 2 trials were used to explore different dosing schedules and identify the appropriate concentrations for further study.

Phase 3 Findings: Efficacy and Outcomes

Phase 3 trials reported findings on the primary outcome measure specified in the study protocols. Studies examined the drug's effect on key endpoints, including measures of pain and functional limitation in participants with moderate-to-severe disease. A key finding reported was an observed change in disease activity measures over 52 weeks.

  • Endpoint Analysis: The proportion of participants achieving the study’s predefined clinical response criteria was reported at intervals such as 12 and 24 weeks.
  • Quality of Life Measures: Research evaluated changes in health-related quality of life assessments reported by participants, including measures of fatigue and sleep disturbance.

Comparative Studies and Safety

Research included studies comparing combination therapy with Brugel to monotherapy (Brugel alone), which evaluated patient-reported outcomes. A meta-analysis of multiple trials reported findings related to patient outcomes when the drug was used in combination versus alone. Trials comparing the drug to existing standard-of-care treatments were also conducted.

Studies did not evaluate the effects of sudden treatment discontinuation, which means information on this specific action is limited in the current literature. Research has included participants with mild kidney impairment; those with severe impairment were often excluded from the studies. Long-term data reported findings related to the maintenance of measures used in the trials.

Frequently Asked Questions (FAQ)

Common questions about Brugel (FAQ)

Q: Is Brugel intended for long-term use?

A: Official administration instructions emphasize that the medication should be used for the shortest duration necessary, as specified in the product labeling. Regulatory documents advise against using the product for a longer time than is necessary or directed.

Q: Do I need regular blood tests while I am taking Brugel?

A: For people taking the active ingredient (Flurbiprofen) systemically or long-term, official documents note that lab work like blood counts and kidney or liver function should be monitored regularly. Information regarding the necessity of monitoring tests should be sought, particularly when using the gel consistently or in the presence of other health conditions.

Q: How does the evidence on Brugel compare with similar drug classes?

A: Clinical research has included studies that compare the effects of Brugel to existing standard-of-care treatments for its approved uses. Research has also compared using the drug alone versus using it as part of combination therapy, with the findings documented in the clinical studies section of the official information.

Q: How is the interaction risk between Brugel and alcohol described in official documents?

A: Official documents caution that the consumption of alcohol may increase the undesirable effects related to the active ingredient, especially those concerning the gastrointestinal tract.

Q: Does Brugel have a brand name or is it only generic?

A: Brugel is the product name for the topical gel formulation containing the active ingredient Flurbiprofen. Flurbiprofen is available as a generic drug. Different formulations containing the same active ingredient may also be sold under various brand names.

Q: Can Brugel make you feel tired or drowsy?

A: The official list of Common adverse effects includes fatigue and dizziness (feeling light-headed). The potential for these effects to impair the ability to drive or operate machinery is noted in the official warnings section.

Q: Is it normal to have mild stomach upset when starting Brugel?

A: Gastrointestinal disturbances such as nausea, diarrhea, dyspepsia (indigestion), and abdominal pain are listed in official documents as Common adverse reactions. Common effects are those that may affect up to 1 in 10 people.

Q: Does Brugel interact with commonly used over-the-counter pain relievers?

A: Regulatory documents advise that use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or high-dose Aspirin is generally not recommended. This warning is present because using both types of medicine together may increase the risk of serious side effects.

Q: Is there a certain food or drink that needs to be avoided while taking Brugel?

A: Official documents note specific cautions regarding alcohol consumption. Beyond alcohol, no general restrictions or warnings related to specific foods or non-alcoholic drinks are routinely listed in the product information.

Q: Can people who are allergic to penicillin take Brugel?

A: Regulatory documents list a contraindication (reason not to use) for individuals with known hypersensitivity to Flurbiprofen, aspirin, or any other NSAID. There is no official statement regarding an allergy to penicillin, as it belongs to a different drug class.

Q: What is the risk of dependence or addiction with Brugel?

A: Brugel’s active ingredient, Flurbiprofen, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The medication is not classified as a controlled substance and is not reported to carry a risk of dependence or addiction.

Q: Is Brugel known to affect blood pressure?

A: Official warnings note that NSAIDs like Flurbiprofen can potentially lead to the new onset of high blood pressure (hypertension) or the worsening of pre-existing high blood pressure. Use of this drug requires caution and monitoring in people with heart-related conditions.

Q: What should I be careful about when combining Brugel with herbal supplements?

A: Official regulatory documents do not specify interactions with every herbal supplement. General patient advice for NSAIDs is often provided to inform a healthcare professional about all supplements used, particularly those that may carry an increased risk of bleeding.

Q: Can Brugel be split or crushed to make it easier to swallow?

A: Brugel is formulated as a topical gel designed only for external application to the skin. The application procedure does not involve swallowing the product, so instructions for splitting or crushing do not apply.

Q: Is it possible to have an allergic reaction to Brugel even after taking it for a while?

A: Official documents list Hypersensitivity reactions as an Uncommon adverse reaction that can occur. The product information does not specify the exact timing (such as immediate versus delayed) of when these reactions may occur.

Q: Are there any warnings about using Brugel before driving or operating machinery?

A: Official warnings exist because the drug can commonly cause side effects like dizziness and fatigue. Official warnings note the potential for these effects to impair the ability to drive or safely operate machinery.

Q: Does Brugel change the way other medications are processed by the body?

A: Official information documents state that the active ingredient can decrease the elimination of some co-administered drugs, such as Lithium and Methotrexate. This may lead to increased plasma concentrations of those medicines, meaning more of the other drug stays in the bloodstream.

Q: Why is Brugel only available with a prescription?

A: The active ingredient, Flurbiprofen, is classified as a Prescription-Only Medicine by regulatory bodies. This status is typically assigned due to the potential for serious adverse systemic effects associated with the NSAID drug class, even when used topically.

Q: Does Brugel commonly cause weight gain or loss?

A: While weight changes are not listed as common side effects, the official safety information does include warnings regarding edema (fluid retention). Edema is associated with the NSAID class of drugs and can lead to observable weight changes.

Q: Does Brugel affect sleep patterns?

A: Clinical research has specifically evaluated changes in patient-reported assessments related to sleep disturbance as part of measuring health-related quality of life outcomes. However, the side effect list does not categorize common sleep pattern changes.

Q: What kind of studies support the use of Brugel?

A: The drug's use is supported by a clinical development program that included Phase 1, Phase 2, and Phase 3 trials. These studies examined safety, identified appropriate dosing, and measured the drug’s effectiveness on pain and functional limitation outcomes.

Q: Can Brugel be used by people with kidney problems?

A: Official eligibility rules state that the drug is contraindicated in patients with severe renal impairment (kidney failure). Use with caution is required for those with mild to moderate kidney impairment due to the drug class risk.

How should Brugel be stored and disposed of?

Storage Conditions

Brugel (Flurbiprofen Topical Gel) must be stored strictly according to the conditions defined in the official regulatory labeling.

Requirement Constraint
Temperature Store at controlled room temperature, typically below 25 C (77 F).
Environmental Must be protected from light and moisture; do not freeze the gel.
Container Keep the medicine in its original container and ensure the cap is tightly closed.

The product must not be used past its printed expiration date. As a mandatory safety measure, the gel must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired gel must be disposed of properly to prevent environmental contamination and accidental exposure. Do not dispose of this medicine by pouring it down a sink or toilet, as it is generally prohibited for non-flush list medicines. Disposal must follow local regulatory requirements for pharmaceutical waste, which often involves returning the product to an authorized drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Brugel found in:

A-Z Index: